These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660 [TBL] [Abstract][Full Text] [Related]
28. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. Moskowitz AJ; Herrera AF; Beaven AW Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645 [TBL] [Abstract][Full Text] [Related]
29. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846 [TBL] [Abstract][Full Text] [Related]
30. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108 [TBL] [Abstract][Full Text] [Related]
31. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390 [TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies. Viviani S; Vanazzi A; Frassoni S; Rusconi C; Rossi A; Romano A; Patti C; Schiavotto C; Sorasio R; Marasco V; Lissandrini L; Rapezzi D; Gottardi D; Cocito F; Mulè A; Leotta S; Gini G; Sorio M; Derenzini E; Rambaldi A; Bagnardi V; Tarella C Leuk Lymphoma; 2024 Apr; 65(4):460-471. PubMed ID: 38164812 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994 [TBL] [Abstract][Full Text] [Related]
35. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246 [TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma. Park K; Yoon DH; Kim S; Park CS; Huh J; Lee SW; Suh C Int J Hematol; 2013 Feb; 97(2):256-62. PubMed ID: 23355263 [TBL] [Abstract][Full Text] [Related]
37. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Tarella C; Cuttica A; Vitolo U; Liberati M; Di Nicola M; Cortelazzo S; Rosato R; Rosanelli C; Di Renzo N; Musso M; Pavone E; Santini G; Pescarollo A; De Crescenzo A; Federico M; Gallamini A; Pregno P; Romano R; Coser P; Gallo E; Boccadoro M; Barbui T; Pileri A; Gianni AM; Levis A Cancer; 2003 Jun; 97(11):2748-59. PubMed ID: 12767087 [TBL] [Abstract][Full Text] [Related]
38. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272 [TBL] [Abstract][Full Text] [Related]
39. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma? Khan N; Moskowitz AJ Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185 [TBL] [Abstract][Full Text] [Related]
40. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience. Mediwake H; Morris K; Curley C; Butler J; Kennedy G Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]